Combination Immunotherapy in Rare Cancers Under InvesTigation

NCT04969887 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Cancer
Neuroendocrine Tumors
Female Reproductive System Neoplasm
MSI-H Solid Malignant Tumor

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Olivia Newton-John Cancer Research Institute

Collaborators

[object Object]